Liquidia’s early buzz for its inhaled lung drug could fade if new prescribers stop coming in and the company stays tied to one narrow market. Add the chance of costly legal setbacks and tougher future trials, and the path to long-term growth may be less smooth than it looks today.Read more
Liquidia is trying to turn its inhaled treprostinil medicine into a broader lung-disease franchise as early signs suggest doctors are switching patients and sticking with the drug. The biggest swing factor is whether legal and competitive pressure derails this rollout or the company can expand into new lung conditions and build a longer-lasting platform.Read more
Liquidia’s new inhaled treatment for pulmonary hypertension is seeing fast early use, and improving insurance coverage could turn that momentum into steadier sales. But a big factory expansion and a second medicine still in development mean the long-term story depends on demand holding up and future results staying supportive.Read more
No trending discussion available.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
